Navigation Links
Interleukin-8, key marker for colorectal cancer treatment
Date:10/9/2007

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.

Although IL-8 expression has been recently correlated with the tumorpathology of various carcinoma types, the role of IL-8 in tumor development and metastasis is still not fully understood and often discussed controversially. Moreover, it remains unclear whether IL-8 expression is related to cancer progression and metastatic potential in colorectal carcinoma tissues.

This issue was addressed by Dr. Rubie and colleagues from the University of the Saarland, Germany. The investigators report on a potential role of IL-8 in the development and metastatic spread of colorectal cancer in the October 7 issue of the World Journal of Gastroenterology.

The article investigates the expression profile of IL-8 in inflammatory (ulcerative colitis), non-malignant (colorectal adenoma) and CRC tissues of different tumor stages as well as in colorectal liver metastases (CRLM) along with their related primary colorectal tumors.

The major findings demonstrate significant IL-8 up-regulation in all inflammatory, non-malignant and malignant colorectal entities compared to their corresponding normal tissues. However, the magnitude of IL-8 expression in surgical CRC tissue specimens correlates with increasing tumor stages and, thus, also with the malignant status of colorectal cancer cells. Moreover, the investigators show for the first time that, irrespective of the tumor stage, IL-8 is significantly higher expressed in CRC tissues compared to inflammatory colorectal conditions and adenomas of the colon/rectum. Since such conditions often constitute prevalent pre-existing disease states in the pathogenesis of colorectal cancer, these results strongly suggest an association between IL-8 up-regulation and the development of CRC. In addition, significant IL-8 overexpression was found in CRLM in comparison to related primary colorectal tumors. Thus, this study not only suggests a correlation between IL-8 expression and the induction and progression of colorectal carcinoma, but also clearly points to a correlation between IL-8 expression and the development of CRLM.

"Monitoring the IL-8 expression level in CRC patients may potentially help to assess the course of cancerous conditions and the prognosis of patients with respect to the development of CRLM. In this respect it is conceivable to monitor the IL-8 expression level in CRC patients that show no diagnosable symptoms of CRLM at the time of presentation, but may still carry a high risk for developing such metastases. A significantly up-regulated level of IL-8 might thus be a useful tool to evaluate the prognosis of patients with CRC with meaningful consequences of treatment. Thus, patients with a higher risk of developing CRLM may receive different treatment compared to patients with a lower risk of developing CRLM."

This study shows that IL-8 may serve as a useful indicator of poor prognosis and a putative target for the development of drugs in CRC therapy.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
86-108-538-1901
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Biomarkers isolated from saliva successfully predict oral and breast cancer
2. UCLA cancer researchers shake loose hidden biomarker
3. Measurement Challenges In Detecting Cancer Biomarkers
4. New markers of climate change
5. U-M scientists discover identifying markers for primitive blood-forming stem cells
6. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
7. Biomarkers may hone anti-aging therapies
8. Making a face: A new and earlier marker of neural crest development
9. Major cancer study aims to identify protein markers for early-stage disease
10. Inflammation markers identify fatigue in breast cancer survivors
11. Viral marker of human migration suspect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and ... (IP) sharing and commercialization model. , The Center for Advancing Innovation helps institutions ... this effort is bringing the IP to the attention of the entrepreneurial community ...
(Date:4/20/2017)... NEW YORK , April 20, 2017 ... industry that focuses on novel drug development and clinical research ... morning are: Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: ... (NASDAQ: ZIOP ). You can access our complimentary ... ...
(Date:4/19/2017)... , ... April 18, 2017 , ... Alisa Wright, founder ... Alumni Awards from the Purdue College of Pharmacy in Lafayette, Indiana. , The ... Program for achievements in their careers and other scientific endeavors. , Wright began ...
(Date:4/19/2017)... ... 19, 2017 , ... ThermaGenix, the PCR Improvement Company, announces ... several other early achievements at ThermaGenix, including the business formation and licensing agreements, ... will use proceeds from the Series A-1 round to:, , ...
Breaking Biology Technology: